ALRN News and Press, Aileron Therapeutics Inc. From 01/12/21

Top Penny Stocks For Your Biotech Watch List This Week With 2021 well on its way, the time to find penny stocks to buy is now. But before making any large investment, it’s important to understand what is going on in the stock market today. Given that the pandemic is still ris...

Bit Digital (BTBT) -19%.TransEnterix (TRXC) -17% on $31.25M registered direct equity offering.Avinger (AVGR) -12%.LM Funding America (LMFA) -12%.GeoVax Labs (GOVX) -10%.Mesoblast (MESO) -10% after presenting heart failure Phase 3 trial results at Investor Healthcare Conference....

Gainers: Zomedica (ZOM) +86%.GeoVax Labs (GOVX) +67%.TransEnterix (TRXC) +65%.Sify Technologies (SIFY) +51%.Mesoblast (MESO) +45%.LM Funding America (LMFA) +36%.Aileron Therapeutics (ALRN) +32%.Energous (WATT) +31%.Acasti Pharma (ACST) +30%.Impinj (PI) +29%.Losers: Applied...

Gainers: GeoVax Labs (GOVX) +83%, Zomedica (ZOM) +82%, TransEnterix (TRXC) +49%, Mesoblast (MESO) +40%, Aileron Therapeutics (ALRN) +29%.Losers: Editas Medicine (EDIT) -16%, Medigus (MDGS) -15%, Jaguar Health (JAGX) -11%, Invita...

Mesoblaston (MESO) +68% after announcing additional results from the DREAM-HF Phase 3 trial.TransEnterix (TRXC) +64%.LM Funding America (LMFA) +49%.Aileron Therapeutics (ALRN) +35%.Bionano Genomics (BNGO) +24% after announcing first publication from the COVID-19 host genome structur...

-- Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceeds to undertake Phase 1b chemoprotection trial of ALRN-6924 in patients with p53...

Are These Robinhood Penny Stocks On Your “Buy” or “Avoid” List This Week? One question traders continue asking themselves is this: “ Are penny stocks worth it? ” It’s not an uncommon question to ask considering the current state o...

Aileron Therapeutics (ALRN) pops 30.37% after a disclosure that Director Muneer A. Satter bought 9M shares in the company.These shares were purchased at a price of $1.10/share, worth $9.9M, taking Satter's indirect ownership to 16.61M shares.Form 4.Previously (Jan. 6): Aileron ...

Aileron Therapeutics ([[ALRN]] -8.8%) has announced the sale of 32.6M of its shares of common stock at $1.10/share, in a registered direct offering priced at-the-market. The offering is expected to complete by January 8.Gross proceeds of $35.9M will be used to fund clinical development o...

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 32,630,983 of its shares of common stock at a purchase price of $1...